ClearNote Health’s Avantect Pancreatic Cancer Test now available to health plan members accessing Claritev’s national PPO networks
ClearNote Health announced an agreement with Claritev, Inc. As part of the agreement, ClearNote Health’s Avantect Pancreatic Cancer Test will now be available to health plan members accessing Claritev’s national PHCS and MultiPlan Networks.
The ClearNote Avantect test is a DNA-based blood test that uses key epigenomic and genomic signals coupled with machine learning to detect the earliest indicators of pancreatic cancer when patients are most likely to benefit from treatment.
The Avantect Pancreatic Cancer Test was designed for patients at high risk of pancreatic cancer, including those newly diagnosed with type 2 diabetes who are at least 50 years old, as well as those with a relevant family history and/or a genetic predisposition. It detects pancreatic cancer by profiling the epigenomic biomarker 5-hydroxymethylcytosine (5hmC) in cell-free DNA and uses advanced AI algorithms to combine that data with other genomic information.
